Research programme: multidrug-resistant antibiotics - Peptilogics

Drug Profile

Research programme: multidrug-resistant antibiotics - Peptilogics

Alternative Names: Antimicrobial peptides - Peptilogics; eCAPS - Peptilogics; engineered Cationic Antimicrobial Peptides - Peptilogics

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptilogics
  • Class Anti-infectives; Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 29 Sep 2017 Preclinical trials in Bacterial infections in USA (IV)
  • 29 Sep 2017 Peptilogics intends to file an IND application for Bacterial infections in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top